Rizatriptan Benzoate Tablet
Product Images NDC 65862-599

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 65862-599). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

A Kaplan-Meier plot showing the estimated probability of achieving an initial headache response within 2 hours post-dose for placebo, Rizatriptan Benzoate 5 mg, and Rizatriptan Benzoate 10 mg. The graph displays higher response probabilities over time for the 10 mg and 5 mg doses compared to placebo, based on pooled data from four placebo-controlled outpatient trials.*

FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

Kaplan-Meier plot showing estimated probability of patients taking a second dose of Rizatriptan Benzoate tablets or other medication for migraines within 24 hours after the initial dose, comparing placebo, Rizatriptan Benzoate 5 mg, and Rizatriptan Benzoate 10 mg groups.*

FDA Label Image

Package Label-principal Display Panel (5 mg Unit-of-Use Pack (12 Tablets))

A line graph comparing the percent response over time (hours post stage 2 dose) for Rizatriptan Benzoate orally disintegrating tablets versus placebo. The x-axis shows hours post dose, and the y-axis shows the percentage with error bars indicating 95% confidence intervals.*

FDA Label Image

Package Label-principal Display Panel (10 mg Unit-of-Use Pack (12 Tablets))

Packaging label for Rizatriptan Benzoate Tablets, USP 5 mg. The label indicates the product contains 12 tablets, arranged as 4 blister cards with 3 tablets each. It is labeled as Rx only and distributed by Aurobindo Pharma USA, Inc. The label includes storage instructions, dosage references, and a barcode.*

FDA Label Image

Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)

Packaging label for Rizatriptan Benzoate Tablets, USP 10 mg, showing a 12-tablet count in 4 blister cards of 3 tablets each. The label is marked for Rx only and includes storage instructions and dosage information. The labeler is Aurobindo Pharma Limited, with distribution noted by Aurobindo Pharma USA, Inc.*

FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical structure of Rizatriptan Benzoate showing its molecular framework including the indole ring system, substituted amine group, and benzoate moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.